Journey Advisory Group LLC Acquires 143 Shares of Stryker Corporation $SYK

Journey Advisory Group LLC lifted its holdings in shares of Stryker Corporation (NYSE:SYK) by 3.3% in the second quarter, Holdings Channel.com reports. The fund owned 4,499 shares of the medical technology company’s stock after purchasing an additional 143 shares during the quarter. Journey Advisory Group LLC’s holdings in Stryker were worth $1,780,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Sachetta LLC lifted its holdings in Stryker by 58.7% during the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after purchasing an additional 27 shares during the last quarter. Goodman Advisory Group LLC bought a new position in Stryker during the 1st quarter valued at about $32,000. Ridgewood Investments LLC lifted its holdings in Stryker by 48.4% during the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock valued at $36,000 after purchasing an additional 30 shares during the last quarter. Ransom Advisory Ltd bought a new position in Stryker during the 1st quarter valued at about $37,000. Finally, Smallwood Wealth Investment Management LLC bought a new position in Stryker during the 1st quarter valued at about $40,000. 77.09% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

SYK has been the subject of several analyst reports. Rothschild Redb raised shares of Stryker to a “hold” rating in a report on Thursday, September 18th. Weiss Ratings reissued a “buy (b-)” rating on shares of Stryker in a report on Wednesday, October 8th. Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a report on Saturday. Redburn Partners set a $420.00 target price on shares of Stryker in a research note on Thursday, September 18th. Finally, Needham & Company LLC boosted their target price on shares of Stryker from $442.00 to $448.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Fifteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $431.76.

Stryker Trading Up 1.5%

Shares of NYSE SYK opened at $374.67 on Monday. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $406.19. The company has a market cap of $143.24 billion, a PE ratio of 49.63, a P/E/G ratio of 2.70 and a beta of 0.94. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The company has a 50-day moving average of $379.40 and a two-hundred day moving average of $378.85.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, topping the consensus estimate of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $5.92 billion. During the same quarter in the previous year, the company earned $2.81 EPS. Stryker’s revenue was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, equities analysts expect that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a dividend of $0.84 per share. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker’s payout ratio is currently 44.50%.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the sale, the director owned 3,222,108 shares in the company, valued at $1,212,962,556.60. The trade was a 5.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Viju Menon sold 500 shares of Stryker stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the sale, the insider owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. This represents a 3.84% decrease in their position. The disclosure for this sale can be found here. 5.20% of the stock is owned by insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.